A Phase 3 interventional study of Ramantamig and Daratumumab in Multiple Myeloma, sponsored by Janssen Research & Development, LLC. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.
Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 126 studies in Multiple Myeloma by Johnson & Johnson — 13 open to participants now, 33 under way, 12 of them phase 3. Multiple Myeloma · Johnson & Johnson.
Among the 126 studies in Multiple Myeloma by Johnson & Johnson, this one is the 2nd largest by planned enrollment of the 100 interventional ones that give a count, is one of 6 that started in 2026, is one of 35 in phase 3, reaches primary completion later than 31 of the 32 other live ones, and was the 126th registered.
3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.
Browse Multiple Myeloma studies →13 of the 126 studies in Multiple Myeloma by Johnson & Johnson are open now, in 12 countries. Recruiting first, the newest first:
Janssen Research & Development, LLC · Sites in Australia, Czechia, France and 11 more countries
Ages 18+
Janssen Research & Development, LLC · Sites in United States, Argentina, Australia and 7 more countries
Ages 18+
Janssen Research & Development, LLC · Sites in United States, Australia, Brazil and 15 more countries
Ages 18+
Janssen Research & Development, LLC · Sites in United States, Australia, Brazil and 12 more countries
Ages 18+
Janssen Research & Development, LLC · Sites in United States, Australia, Spain
Ages 18–80
By country, each count listing its studies:
Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
126 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 28 · Phase 2 37 · Phase 3 36 · Phase 4 4
First in 1995; this study’s year is marked. 6 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,000 is above the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.
Median enrollment 125 across the 100 interventional studies, 255 across the 18 observational. Of the 82 that completed or were terminated, 33 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Janssen Research & Development, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.
Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.
9 of the studies in Multiple Myeloma by Johnson & Johnson that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05455320Phase 3Janssen Research & Development, LLCA Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment | 2027-07-30 |
| NCT07030517Johnson & Johnson Private LimitedA Study to Assess Safety of Teclistamab in Indian Participants With Relapsed and Refractory Multiple Myeloma | 2027-02-12 |
| NCT04133636Janssen Research & Development, LLCA Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma | 2027-02-26 |
| NCT04108195Janssen Research & Development, LLCA Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma | 2027-04-07 |
| NCT05652335Janssen Research & Development, LLCA Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis | 2027-04-19 |
Add all 9 to your calendar (.ics) → With an account.
Among the 126 studies in Multiple Myeloma by Johnson & Johnson, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare how well Ramantamig plus Daratumumab (ramantamig-D) works compared with a treatment that includes Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd), followed by high-dose therapy, autologous stem cell transplantation (using the participant's own stem cells), and maintenance treatment with Daratumumab and Lenalidomide (DR) in participants with newly diagnosed multiple myeloma (NDMM), a blood cancer affecting plasma cells, who are eligible for transplant.
TRIlogy-6 trial is being conducted by 2 sponsors: J\&J (N=325) and EMN (N=675); the combined total of 1000 participants enrolled by both sponsors will be analyzed.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive subcutaneous (SC) dose of ramantamig-D.
Drug: Ramantamig · Drug: Daratumumab
Participants will receive Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) along with High-Dose Therapy (HDT), Autologous Stem Cell Transplantation (ASCT) and Daratumumab and Lenalidomide (DR) maintenance for 2 years or until progressive disease (PD) or intolerable toxicity whichever occurs first. Participants will have the option to continue lenalidomide and/or daratumumab maintenance therapy beyond 2 years, until PD, at the investigator's discretion and sponsor approval.
Drug: Daratumumab · Drug: Bortezomib · Drug: Lenalidomide · Drug: Dexamethasone · Drug: HDT+ASCT
Ramantamig will be administered as subcutaneous (SC) injection.
Also known as: JNJ-79635322
Daratumumab will be administered as SC injection.
Also known as: JNJ-54767414
Bortezomib will be administered as SC injection.
Lenalidomide will be administered orally.
Dexamethasone will be administered orally or intravenously (IV).
HDT and ASCT will be performed as per standard of care.
Progression-Free Survival (PFS)
PFS is defined as the duration from the date of randomization to either confirmed progressive disease (PD) or death, whichever occurs first. PD will be determined according to international myeloma working group (IMWG) response criteria.
Time frame: Up to approximately 10 years
Percentage of Participants Achieving 12-Month Minimal Residual Disease (MRD)-Negative Complete Response (CR)
12-month MRD-negative CR is defined as participants who achieve MRD-negative status at 12 months (plus minus \[+-\] 3 months) from randomization, as determined by next-generation sequencing (NGS), prior to PD or subsequent antimyeloma therapy (including autologous stem cell transplantation \[ASCT\]).
Time frame: Up to approximately 12 months
Overall Survival (OS)
OS is defined as the time from the date of randomization to the date of the participant's death due to any cause. If the participant is alive or the vital status is unknown, then the participant's data will be censored at the date the participant was last known to be alive.
Time frame: Up to approximately 10 years
Percentage of Participants Achieving 24-Month Sustained MRD-Negative CR
24-month sustained MRD-negative CR is defined as participants who achieve MRD-negative CR status, as determined by NGS, for at least 24 months without any examination showing MRD positive status in between, and prior to PD or subsequent antimyeloma therapy (including ASCT).
Time frame: Up to 5 years
Percentage of Participants with Very Good Partial Response (VGPR) or Better
VGPR or better is defined as participants who achieve VGPR, CR, or stringent complete response (sCR) prior to subsequent antimyeloma therapy, in accordance with the IMWG criteria, during or after the trial intervention.
Time frame: Up to 5 years
Percentage of Participants with Complete Response (CR) or Better
CR or better is defined as participants who achieve CR or sCR prior to subsequent antimyeloma therapy, in accordance with the IMWG criteria, during or after the trial intervention.
Time frame: Up to 5 years
Percentage of Participants with Overall Response (ORR)
Overall response rate is defined as percentage of participants who achieve partial response (PR) or better prior to subsequent antimyeloma therapy, in accordance with the IMWG criteria, during or after the trial intervention.
Time frame: Up to 5 years
Percentage of Participants with Overall MRD-Negative CR
Overall MRD-negative CR is defined as participants who achieve MRD negative status, as determined by NGS, at any time point after randomization and prior to PD or subsequent antimyeloma therapy and who achieve CR or better.
Time frame: Up to 5 years
Percentage of Participants Achieving 12-Month Sustained MRD-Negative CR
12-month sustained MRD-negative CR is defined as participants who achieve MRD-negative CR status, as determined by NGS, for at least 12 months without any examination showing MRD positive status in between, and prior to PD or subsequent antimyeloma therapy (including ASCT).
Time frame: Up to 5 years
Progression-Free Survival 2 (PFS2)
PFS2 is defined as the time interval between the date of randomization and date of event, which is defined as PD, as assessed by investigator, on the first subsequent line of antimyeloma therapy or death from any cause, whichever occurs first.
Time frame: Up to approximately 10 years
Number of Participants With Treatment-Emergent Adverse Event (TEAE) by Severity
An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non investigational) product. Any new or worsening AE occurring at or after the initial administration of study treatment through the day of last dose plus 30 days or prior to the start of subsequent anticancer therapy will be considered treatment-related regardless of the start date of the event. TEAEs will be graded according to the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 6.0. Severity scale ranges from Grade 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening, Grade 5= death related to adverse event.
Time frame: Up to approximately 10 years
Number of Participants With Adverse Events by Severity
An AE is any untoward medical occurrence in a clinical trial participant administered a pharmaceutical (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the treatment.
Time frame: Up to approximately 10 years
Number of Participants with Significant Abnormalities in Laboratory Parameters
Number of participants with abnormalities in laboratory parameters (serum chemistry and hematology) will be reported.
Time frame: Up to approximately 10 years
Change from Baseline in Health-related Quality of Life (HRQoL), Symptoms and Functioning Using the Multiple Myeloma Symptom and Impact Questionnaire (MySIm-Q) Scale Scores
The MySIm-Q is a disease-specific patient reported outcome (PRO) assessment with established content validity for participants with newly diagnosed multiple myeloma (NDMM). It is included to be complementary to the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30). It includes 17 items resulting in a symptom subscale and an impact subscale. The recall period is the "past 7 days" and responses are reported on a 5-point verbal rating scale. Higher scores indicate greater severity/impact.
Time frame: From Baseline up to approximately 10 years
Change from Baseline in HRQoL, Symptoms and Functioning Using the EORTC QLQ C30 Scale Scores
The EORTC QLQ-C30 Version 3 includes 30 items that make up 5 functional scales (physical, role, emotional, cognitive, and social); 1 global health status scale; 3 symptom scales (pain, fatigue, and nausea/vomiting); 5 single symptom items (dyspnea, insomnia, appetite loss, constipation, and diarrhea); and a single impact item (financial difficulties). The item and scale scores are transformed to a 0 to 100 scale. A higher score represents greater HRQoL, better functioning, and more (worse) symptoms.
Time frame: From Baseline up to approximately 10 years
Change from Baseline in HRQoL, Symptoms and Functioning Using European Quality of Life 5-Dimensions 5-Level Version (EQ-5D-5L) Scale Scores
The EQ-5D-5L is a self-administered, generic health status measure, consisting of a descriptive system and a visual analogue scale (EQ-VAS). The descriptive system covers 5 dimensions of health (mobility, self-care, usual activities, pain or discomfort, and anxiety or depression), each with 5 levels of severity (no problems, slight problems, moderate problems, severe problems, and unable to perform or extreme problems). Higher scores indicate worse HRQoL.
Time frame: From Baseline up to approximately 10 years
Time to Worsening in HRQoL, Symptoms and Functioning Using the MySIm-Q Scale Scores
Time to worsening in HRQoL, symptoms and functioning using the MySIm-Q scale scores will be reported. The recall period is the "past 7 days" and responses are reported on a 5-point verbal rating scale. Higher scores indicate greater severity/impact.
Time frame: Up to approximately 10 years
Time to Worsening in HRQoL, Symptoms and Functioning Using the EORTC-QLQ-C30 Scale Scores
Time to worsening in HRQoL, symptoms and functioning using the EORTC-QLQ-C30 scale scores will be reported. The item and scale scores are transformed to a 0 to 100 scale. A higher score represents greater HRQoL, better functioning, and more (worse) symptoms.
Time frame: Up to approximately 10 years
Time to Worsening in HRQoL, Symptoms and Functioning Using the EQ-5D-5L Scale Scores
Time to worsening in HRQoL, symptoms and functioning using the EQ-5D-5L scale scores will be reported. The EQ-5D-5L descriptive system covers 5 dimensions of health each with 5 levels of severity with higher scores indicating worse HRQoL.
Time frame: Up to approximately 10 years
Percentage of Participants With Meaningful Improvement in HRQoL, Symptoms and Functioning Using the MySIm-Q Scale Scores
Percentage of participants with meaningful improvement in HRQoL, symptoms and functioning using MySIm-Q scale score will be reported. The recall period is the "past 7 days" and responses are reported on a 5-point verbal rating scale. Higher scores indicate greater severity/impact.
Time frame: Up to approximately 10 years
Percentage of Participants With Meaningful Improvement in HRQoL, Symptoms and Functioning Using the EORTC-QLQ-C30 Scale Scores
Percentage of participants with meaningful improvement in HRQoL, symptoms and functioning as assessed by EORTC-QLQ-C30 scale score will be reported. he item and scale scores are transformed to a 0 to 100 scale. A higher score represents greater HRQoL, better functioning, and more (worse) symptoms.
Time frame: Up to approximately 10 years
Percentage of Participants With Meaningful Improvement in HRQoL, Symptoms and Functioning Using the EQ-5D-5L Scale Scores
Percentage of participants with meaningful improvement in HRQoL, symptoms and functioning using EQ-5D-5L scale score will be reported. The EQ-5D-5L descriptive system covers 5 dimensions of health each with 5 levels of severity with higher scores indicating worse HRQoL.
Time frame: Up to approximately 10 years
Percentage of Participants Who Report Side Effect Burden as Assessed by the European Organization for Research and Treatment of Cancer Item List (EORTC IL) 46
The EORTC IL46 consists of a single question that measures global impression of burden due to treatment-related symptoms. The response options range from "not at all" to "very much" on a 4 point scale.
Time frame: Up to approximately 10 years
No study locations are listed for this record.
Plan to share: Yes — The data sharing policy of Johnson \& Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu.
Data sharing details ↗ · innovativemedicine.jnj.com
No publications or documents are linked to this record.
Start is estimated for Dec 2026; primary completion for Jan 2037, 120 months later.
Of 107 industry-sponsored phase 3 interventional studies under Multiple Myeloma, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 66. This study's planned 120 months is above that.
Counting every sponsor, half of 178 studies reached it within 55 months; a quarter within 34 and three quarters within 95.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ramantamig
Janssen Research & Development, LLC →